Literature DB >> 22930108

[Nervous system side effects of disease modifying treatments of rheumatoid arthritis].

A Rubbert-Roth1, H-F Petereit.   

Abstract

Antirheumatic medication is of crucial importance within the treatment concept of chronic inflammatory disorders. Side effects may affect various organ systems, among which are neurologic manifestations. If patients have comorbidities involving the nervous system this should be taken into consideration before choosing an individual immunosuppressant or immunomodulatory compound, as any worsening of the underlying neurologic disease should be avoided. In this article, relevant neurologic disorders will be described with respect to the clinical manifestations, differential diagnosis and treatment. In the second part, pharmaceuticals and biologicals which are frequently used as part of an antirheumatic regimen are discussed with respect to the potential to induce side effects specifically related to the nervous system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930108     DOI: 10.1007/s00393-012-0959-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  43 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

2.  Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients.

Authors:  V Dubois; H Dutronc; M E Lafon; V Poinsot; J L Pellegrin; J M Ragnaud; A M Ferrer; H J Fleury
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

3.  Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica.

Authors:  Alejandro Sánchez-Carteyron; Raquel Alarcia; José Ramón Ara; Jesús Martín
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

4.  A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Authors:  Elliot M Frohman; Gary Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 5.  Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.

Authors:  Leonard H Calabrese; Eamonn S Molloy; DeRen Huang; Richard M Ransohoff
Journal:  Arthritis Rheum       Date:  2007-07

6.  Leflunomide-associated progressive multifocal leukoencephalopathy.

Authors:  Megan Rahmlow; Elizabeth A Shuster; Jacob Dominik; H Gordon Deen; Dennis W Dickson; Allen J Aksamit; Hector A Robles; William D Freeman
Journal:  Arch Neurol       Date:  2008-11

Review 7.  Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Authors:  Daniel L Keene; Carole Legare; Elaine Taylor; Jim Gallivan; Gloria Mah Cawthorn; Duc Vu
Journal:  Can J Neurol Sci       Date:  2011-07       Impact factor: 2.104

8.  Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature.

Authors:  Yuki Ishikawa; Naoichiro Yukawa; Koichiro Ohmura; Yuji Hosono; Yoshitaka Imura; Daisuke Kawabata; Takaki Nojima; Takao Fujii; Takashi Usui; Tsuneyo Mimori
Journal:  Clin Rheumatol       Date:  2010-02-09       Impact factor: 2.980

9.  Magnetization transfer imaging provides no evidence of demyelination in methotrexate-induced encephalopathy.

Authors:  F R Miese; F R Schuster; K Pierstorff; M Karenfort; H J Laws; A Borkhardt; A Saleh
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-22       Impact factor: 3.825

10.  Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA).

Authors:  Katsuya Kobayashi; Yoko Okamoto; Haruhisa Inoue; Takashi Usui; Masafumi Ihara; Jun Kawamata; Yukio Miki; Tsuneyo Mimori; Hidekazu Tomimoto; Ryosuke Takahashi
Journal:  Intern Med       Date:  2009-08-03       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.